Medical significance of endothelial glycocalyx. Part 2: Its role in vascular diseases and in diabetic complications;Importancia médica del glucocáliz endotelial. Parte 2: Su papel en enfermedades vasculares y complicaciones de la diabetes mellitus

Archivos de Cardiologia de Mexico

Volumn 84, Issue 2, 2014, Pages 110-116

  Frati Munari, Alberto C ^a  

^a LIVER RESEARCH UNIT   (Mexico)

Author keywords

Atherosclerosis; Chronic venous disease; Endothelial dysfunction; Glycocalyx; Mexico; Sulodexide

Indexed keywords

GLYCOPROTEIN; GLYCOSAMINOGLYCAN; PROTEOGLYCAN; SULODEXIDE;

ALBUMINURIA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FILTRATION; GLYCOCALYX; HUMAN; LEUKOCYTE; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; VASCULAR DISEASE; VEIN DISEASE; CHEMISTRY; CHRONIC DISEASE; DIABETIC ANGIOPATHIES; DRUG EFFECTS; PATHOLOGY; PHYSIOLOGY; VASCULAR DISEASES; VASCULAR ENDOTHELIUM; VENOUS PRESSURE;

ATHEROSCLEROSIS; CHRONIC DISEASE; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; GLYCOCALYX; GLYCOSAMINOGLYCANS; HUMANS; VASCULAR DISEASES; VENOUS PRESSURE;

EID: 84902795323     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acmx.2013.10.006     Document Type: Short Survey

References (58)

1. Frati-Munari AC. Importancia médica del glucocáliz endotelial. Arch Cardiol Mex. 2013;83:303-12
2. Raines EW. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationship to vascular disease. Int J Exper Pathol. 2000;81:173-82
3. Libby P, Ridker PM, Hansson GK. Inflammation in aterosclerosis: From pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-38
4. Chiu JJ, Chen S. Effects of disturbed flow on vascular endothelium: Pathophysiological basis and clinical perspectives. Physiol Rev. 2011;91:327-87
5. Van den Bergh BM, Spaan JAE, Rolf TM, et al. Atherogenic región and diet diminish glycocalyx dimensión and increase intimamedia ratios at the murine carotid artery bifurcation. Am J Physiol Heart Circ Physiol. 2006;290:H915-20
6. Chien SS. Molecular and mechanical bases of focal lipid accumulation in arterial wall. Prog Biophys Mol Biol. 2003;83:131-51
7. Governeur M, van den Berg B, Nieuwdorp M, et al. Vasculoprotective properties of the endotelial glycocalyx: Effects of fluid shear stress. J Intern Med. 2006;259:393-400
8. Gross ER, LaDisa JR, Weihrauch D, et al. Reactive oxygen species modulate coronary wall shear stress and endothelial function during hyperglycemia. Am J Physiol Heart Circ Physiol. 2003;284:H1552-9
9. Kelly R, Ruane-O'Hora T, Noble MIM, et al. Differential inhibition by hyperglycaemia of shear stress-but not acetylcholinemediated dilatation in the artery of anaesthetized pig. J Physiol. 2006;573:133-45
10. Agus GB, Mattana P, Carelli F. Monitor 2010: Italian epidemiological survey on chronic venous diseases. Acta Phlebol. 2012;13:9-17
11. Secomb TW, Hsu R, Pries AR. Effect of the endotelial surface layer on transmission of fluid shear stress to endothelial cells. Biorrheology. 2001;38:143-50
12. Becker BF, Chappel D, Bruegger D, et al. Therapeutic strategies targeting the endothelial glycocalyx: Acute deficits, but great potential. Cardiovasc Res. 2010;87:300-10
13. Bergan JJ, Schmid-Schönbein GW, Coleridge-Smith PD, et al. Chronic venous disease. N Engl J Med. 2006;355:488-98
14. Ono T, Bergan JJ, Schmid-Schönbein GW, et al. Monocyte infiltration into venous valves. J Vasc Surg. 1998;27:158-66
15. Nicolaides AN. Chronic venous disease and the leukocyteendothelium interaction: From symptoms to ulceration. Angiology. 2005;56 Suppl 1:S11-9
16. Raffetto JD, Khalil RA. Mechanisms of varicose vein formation: Valve dysfunction and wall dilation. Phlebology. 2008;23: 85-98
17. Simka M. Cellular and molecular mechanisms of venous ulcer development. The «puzzle» theory. Int Angiol. 2010;29:1-19
18. Brooks EG, Trotman W, Wadsworth MP, et al. Valves of the deep venous system: an overlooked risk factor. Blood. 2009;114:1276-9
19. Furtner M, Kielchl S, Mair A, et al. Urinary albumin excretion is independently associated with carotid and femoral artery aterosclerosis in the general population. Eur J Cardiol. 2005;26:279-87
20. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: A role for the glomerular endothelium? Diabetologia. 2008;51:714-25
21. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32:219-26
22. Nieuwdorp M, van Haeften TW, Gouverneur MCLG, et al. Loss of endotelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes. 2006;55:480-6
23. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes. 2005;54:1615-25
24. Mulivor AW, Lipowsky HH. Role of glycocalyx in leukocyteendothelial cell adhesión. Am J Physiol Heart Circ Physiol. 2002;283:H1282-91
25. Constantinescu AA, Vink H, Spaan JAE. Endothelial cell glycocalyx modulates immobilization of leukocytes at the endotelial surface. Arterioscler Thromb Vasc Biol. 2003;23:1541-7
26. Butler LM, Rainger GE, Nash GB. A role for the endotelial glycosaminoglycan hyaluronan in neutrophil recruitment by endotelial cells cultured for prolonged periods. Exp Cell Res. 2009;315:3433-41
27. Nieuwdorp M, Meuwese MC, Vink H, et al. The endothelial glycocalyx: A potential barrier between health and vascular disease. Curr Opin Lipidol. 2005;16:507-11
28. Becker BF, Chappell D, Bruegger D, et al. Therapeutic strategies targeting the endothelial glycocalyx: Acute deficits, but great potential. Cardiovasc Res. 2010;87:300-10
29. Noble MIM, Drake-Holland AJ, Vink H. Hypothesis: Arterial glycocalyx dysfunction is the first step in the atherothrombotic process. QJM. 2008;101:513-8
30. Noble MIM, Drake-Holland AJ. Review: Hyperglycemia and the vascular glycocalyx: the key to microalbuminuria and cardiovascular diseae in diabetes mellitus? Br Med J Diab Vasc Dis. 2010;10:66-70
31. Meuwese MC, Mooij HL, Nieuwdorp M, et al. Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia. J Lipid Res. 2009;50:148-53
32. Moseley R, Waddington RJ, Embery G. Degradation of glycosaminoglycans by reactive oxigen species derived from stimulated polymorfonucleal leukocytes. Biochem Biophys Acta. 1997;1362:221-31
33. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with _-lipoic acid improves symptomatic diabetic polyneuropathy. Diabetes Care. 2006;29:2365-70
34. Haremberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998;18:1-20
35. Ofosu FA. Pharmacological actions of sulodexide. Sem Thromb Hemost. 1998;24:127-38
36. Broekhuisen LN, Meuwese MC, Mooij HL, et al. Sulfated glycosaminoglycans restore glycocalyx barrier of cultured endothelial cells under hyperglycemic conditions. En: Meuwese MC, editor. Targeting the vessel wall in cardiovascular prevention. Amsterdam: Univ. Amsterdam; 2008., ISBN 9789085594024 p. 46-54[consultado 30 Ago 2010]. Disponible en: http://dare.uva.nl/ document/112476
37. Mathison Y, Garrido MR, Israel A, et al. Efecto del glicosaminoglicano sulodexida sobre la actividad de la sintasa de óxido nítrico en la corteza renal de ratas con diabetes tipo 1. Rev Latinoamer Hipert. 2008;3:182-9
38. Kristová V, Lisková S, Sotniková R, et al. Sulodexide improves endotelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res. 2008;57:491-4
39. Vasquez J, Mathison Y, Romero-Vecchione E, et al. Efecto del sulodexide sobre la capacidad de relajación y alteraciones estructurales de la arteria aorta en ratas diabéticas por estreptozotocina. Invest Clin. 2010;51:467-77
40. Park HY, Kang S, Kim GY, et al. Inhibition of neointimal proliferation of rat carotid artery by sulodexide. J Korean Med Sci. 1997;12:210-4
41. Rubio-Gayosso I, Platts SH, Duling BR. Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;290:H2247-56
42. Lauver DA, Booth EA, White AJ, et al. Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther. 2005;312:794-800
43. Ciszewicz M, Polubinska A, Antoniewicz A, et al. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res. 2009;153:118-23
44. Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010;53:2646-55
45. Jin HY, Lee KA, Song SK, et al. Sulodexide prevents peripheral nerve damage in streptozotocin induced diabetic rats. Eur J Pharmacol. 2012;674:217-26
46. Mannello F, Raffetto JD. Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: The linkage among cell biology, pathology and translational research. Am J Transl Res. 2011;3:149-58
47. Andreozzi GM. Sulodexide in the treatment of cronic, venous disease. Am J Cardiovasc Drugs. 2012;12:73-81, http://dx.doi. org/10.2165/11599360
48. Scondotto G, Aloisi D, Ferrari P, et al. Treatment of venous leg ulcers with sulodexide. Angiology. 1999;50:883-9
49. Coccheri S, Scondotto G, Agnelli G, et al., Venous arm of the SUAVIS (Sulodexide Arterial Venous Italian Study) group. Randomised, double-blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost. 2002;87:947-52
50. Kucharzewski M, Franec A, Hoziolek H. Treatment of venous leg ulcers with sulodexide. Phlebologie. 2003;32: 115-20
51. Gaddi A, Galetti C, Illuminati B, et al. Meta-analysis of some results of clinical trial son sulodexide therapy in peripheral occlusive arterial disease. J Int Med Res. 1996;24: 389-406
52. Coccheri S, Scondotto G, Agnelli G, et al., Arterial arm of the Suavis (Sulodexide Arterial Venous Italian Study) group. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J. 2002;23:1057-65
53. Della Marchina M, Bellucci M, Palazzini E. Medium term oral sulodexide treatment of diabetic patients suffering from peripheral arterial obstructive disease: A double-blind, placebo-controlled study. Progress Rep. 1992;4:5-15
54. Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Assoc Nephrol. 2002;13:1615-25
55. Weiss R, Niecestro R, Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs. 2007;67:2681-96
56. Tufano A, Arturo C, Cimino E, et al. Mesoglycan: Clinical evidences for use in vascular disease. In J Vasc Med. 2010;2010:396043, http://dx.doi.org/10.1155/2010/396043 [consultado 13 Ago 2012]
57. Trejo-Gutiérrez JF, López-Jiménez F. Cardiología «basada en evidencia»: aplicaciones prácticas de la epidemiología. I. La valoración de medicamentos o terapias novedosas. Arch Cardiol Mex. 2011;81:47-52
58. Rodríguez-Escudero JP, López-Jiménez F, Trejo-Gutiérez JF. Cardiología «basada en evidencia»: aplicaciones prácticas de la epidemiología. IV. Modelos de predicción de riesgo cardiovascular. Arch Cardiol Mex. 2012;82:66-72.